List of Excipients in Branded Drug OPDIVO

« Back to Dashboard

OPDIVO Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

OPDIVO (nivolumab) is a high-value monoclonal antibody product whose excipient strategy is built around protein stability, low particulate formation, oxidation control, and compatibility with intravenous and subcutaneous delivery. The commercial opportunity is concentrated in high-purity excipients, hyaluronidase-enabled delivery, container-closure systems, analytical testing, and formulation services rather than conventional generic substitution.

OPDIVO is marketed by Bristol Myers Squibb as an intravenous formulation and, since 2024, as OPDIVO QVANTIG, a subcutaneous combination of nivolumab and recombinant human hyaluronidase. The subcutaneous product expands the excipient opportunity because it requires a higher-concentration, viscosity-controlled formulation and a second active biological component.[1,2]

What excipients are used in the OPDIVO intravenous formulation?

The FDA-approved OPDIVO injection contains a conventional low-pH antibody formulation with mannitol, pentetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection.[1]

Component	Function in OPDIVO formulation	Commercial relevance
Nivolumab	Anti-PD-1 monoclonal antibody	Primary active ingredient
Mannitol	Bulking agent and tonicity modifier	Large-volume, compendial supply market
Pentetic acid	Chelating agent	Controls trace-metal catalyzed degradation
Polysorbate 80	Surfactant	Limits interfacial adsorption and aggregation
Sodium citrate dihydrate	Buffer component	Controls formulation pH
Sodium chloride	Tonicity adjustment	Standard parenteral excipient
Water for injection	Vehicle	Sterile manufacturing requirement

The commercial formula uses established excipients, but biologic-grade quality requirements are materially stricter than ordinary small-molecule supply requirements. Critical attributes include low peroxide content, low subvisible particle burden, low bioburden, endotoxin control, lot-to-lot consistency, and compatibility with stainless-steel, polymer, glass, and tubing contact surfaces.

The formulation pH is approximately 6.0. The product is supplied as a sterile solution at 10 mg/mL in single-dose vials, with product concentrations and vial presentations varying by market and product configuration.[1]

Why is polysorbate 80 strategically important for OPDIVO?

Polysorbate 80 is the most formulation-sensitive conventional excipient in OPDIVO. It protects nivolumab from adsorption to vial, syringe, infusion-bag, and tubing surfaces. It also reduces agitation-induced aggregation during shipping and handling.

The main risks are:

• Peroxide-driven antibody oxidation.
• Hydrolysis of fatty-acid esters.
• Formation of subvisible and visible particles.
• Lot variability in surfactant composition.
• Interaction with silicone oil and container-closure components.
• Degradation during long-term refrigerated storage.

These risks create opportunities for suppliers of pharmaceutical-grade polysorbate 80 with tighter peroxide specifications, improved analytical characterization, and controlled fatty-acid profiles. Suppliers that can offer highly characterized polysorbate 80, polysorbate 20 alternatives, or novel nonionic surfactants may compete for future formulation programs, but substitution would require extensive comparability and stability work.

A change from polysorbate 80 to another surfactant would generally be a high-risk change for a marketed biologic. Depending on the manufacturing and formulation change, Bristol Myers Squibb could need comparative stability studies, process validation, extractables and leachables work, and a prior approval supplement or other FDA filing under biologics postapproval-change guidance.[3]

What excipient strategy does OPDIVO QVANTIG require?

OPDIVO QVANTIG adds a subcutaneous delivery platform to nivolumab. The product contains nivolumab and recombinant human hyaluronidase, which temporarily modifies the extracellular matrix to permit subcutaneous administration of a larger injection volume.[2]

The commercial formulation challenge is different from the intravenous product. A subcutaneous formulation must address:

• High protein concentration.
• Local tissue tolerability.
• Injection force and delivery time.
• Viscosity.
• Protein aggregation.
• Hyaluronidase activity.
• Compatibility between nivolumab and hyaluronidase.
• Stability in the final container and delivery device.

Hyaluronidase is not a conventional inactive excipient in the regulatory sense. It is a separate active biological component that enables the route of administration. Its inclusion increases manufacturing complexity, analytical requirements, intellectual-property exposure, and supply-chain risk.

Commercial opportunities created by the subcutaneous product

The subcutaneous presentation expands demand for:

1. Recombinant human hyaluronidase or comparable extracellular-matrix-modifying enzymes.
2. High-concentration antibody formulation development.
3. Low-shear filling and mixing equipment.
4. Prefilled syringes, on-body delivery systems, and injection devices.
5. Silicone-oil and tungsten control for primary containers.
6. Particle-monitoring and protein-aggregation assays.
7. Human-factor and usability testing.
8. Cold-chain packaging for combination biologics.

The strongest commercial position is likely to belong to suppliers with both hyaluronidase manufacturing capability and regulatory experience in combination products. Commodity excipient suppliers have a smaller opportunity unless they can provide high-purity, low-variability material with a strong regulatory file.

What formulation patents protect OPDIVO and OPDIVO QVANTIG?

OPDIVO’s core intellectual-property position is principally associated with nivolumab, anti-PD-1 antibodies, therapeutic uses, manufacturing, and route-of-administration technologies. The exact protection varies by jurisdiction and by patent family.

Formulation suppliers should distinguish four protection categories:

IP category	Relevance to excipient strategy	Typical commercial effect
Antibody composition patents	Protect nivolumab or related anti-PD-1 antibodies	High barrier to biosimilar entry
Method-of-use patents	Protect treatment of specific cancers or treatment combinations	May limit label-based substitution
Formulation patents	Protect concentrations, buffers, surfactants, stability systems, or combinations	Can delay formulation substitution
Delivery patents	Protect subcutaneous administration, hyaluronidase combinations, or devices	Important for OPDIVO QVANTIG competitors

A conventional excipient such as mannitol, sodium chloride, citrate, or polysorbate 80 is unlikely to be protectable in isolation when used in a known biologic formulation. Protection may arise from a specific combination, concentration range, pH, protein concentration, stability profile, or delivery configuration.

Patent expiration must be assessed by family, claim scope, terminal disclaimers, patent-term adjustment, pediatric extensions, and jurisdiction. The FDA does not publish an Orange Book listing for OPDIVO because Orange Book listings principally cover approved small-molecule drug products. Biologic-related patent and exclusivity analysis is conducted through the Purple Book, FDA biologics records, patent databases, and court filings.[4,5]

When does OPDIVO lose regulatory exclusivity?

OPDIVO is a biologic licensed under a Biologics License Application, not a conventional New Drug Application. Its reference-product exclusivity is therefore assessed under the Biologics Price Competition and Innovation Act framework.

The key milestones are:

Milestone	Date or status
Original FDA approval of OPDIVO	December 2014
Reference-product BPCIA exclusivity	Generally 12 years from first licensure
Expected baseline end of reference-product exclusivity	December 2026
OPDIVO QVANTIG FDA approval	2024
Biosimilar pathway	Available after applicable statutory and patent requirements
Orange Book status	Not applicable as the primary biologic patent listing source
Purple Book status	Relevant FDA reference-product database

The December 2026 date is a regulatory exclusivity milestone, not an automatic market-entry date. Biosimilar launch timing will depend on patent resolution, FDA approval, interchangeability status, manufacturing readiness, and settlement terms.

Supplemental approvals for new indications or delivery formats do not automatically create a new 12-year reference-product exclusivity period. A separate exclusivity analysis is required for OPDIVO QVANTIG and any future product configuration.

What generic and biosimilar entry risks exist for OPDIVO?

Traditional generic entry is not the relevant pathway. The competitive threat is biosimilar or interchangeable-biologic entry for nivolumab.

Potential entrant strategies include:

• A biosimilar to intravenous nivolumab.
• A biosimilar with a narrower indication set.
• A product designed for oncology infusion centers.
• A subcutaneous nivolumab product using a different delivery approach.
• A nivolumab-hyaluronidase combination.
• A competing anti-PD-1 antibody with lower administration cost.

A biosimilar applicant may avoid certain method-of-use claims through a "skinny label" approach, subject to statutory and litigation constraints. Formulation patents may be less important than antibody composition, manufacturing, analytical comparability, and clinical-use claims, but they can still affect the timing and economics of launch.

The principal technical barriers are:

• Demonstrating analytical similarity for a complex monoclonal antibody.
• Matching aggregation and charge-variant profiles.
• Reproducing glycosylation within a clinically acceptable range.
• Establishing a scalable cell-culture and purification process.
• Controlling residual host-cell proteins and DNA.
• Matching stability through the proposed shelf life.
• Establishing interchangeability where commercially valuable.

How strong is the OPDIVO patent estate for excipient suppliers and competitors?

The estate is strongest where formulation or delivery claims are tied to the nivolumab molecule, a defined concentration, a specific route, or a proprietary combination such as nivolumab with hyaluronidase. It is weaker for unclaimed commodity excipients used in routine parenteral formulations.

Area	Relative barrier	Reason
Nivolumab antibody sequence and structure	High	Core biologic identity
Anti-PD-1 therapeutic use	High	Broad oncology applications and combinations
Intravenous formulation	Medium to high	Depends on claim scope and expiration
Polysorbate 80 or mannitol alone	Low	Generally established excipients
Nivolumab-hyaluronidase combination	High	Combination and delivery claims
Device and administration system	Medium to high	May create separate patent layers
Manufacturing process	High where process-specific	Difficult to design around and validate

For excipient companies, the principal legal risk is usually indirect. A supplier may sell an excipient without infringing a drug patent, but its customer’s formulation, process, or delivery system may fall within a protected claim. Supplier agreements should address specifications, change notification, regulatory support, indemnity, and ownership of formulation data.

Which companies can benefit from OPDIVO excipient demand?

The opportunity divides among several supplier classes.

Pharmaceutical excipient manufacturers

Mannitol, sodium chloride, citrate, and polysorbate 80 are supplied by multiple global pharmaceutical-material companies. Differentiation depends on:

• Injectable-grade manufacturing.
• Global regulatory support.
• Excipient master files or equivalent documentation.
• Supply redundancy.
• Low extractables and leachables.
• Stability data in monoclonal-antibody formulations.
• Change-control discipline.

Biologic formulation specialists

Contract development and manufacturing organizations can support:

• High-concentration nivolumab formulations.
• Subcutaneous viscosity reduction.
• Forced-degradation studies.
• Surfactant screening.
• Freeze-thaw and agitation studies.
• Container-closure compatibility.
• Scale-up and aseptic filling.

Hyaluronidase suppliers

Hyaluronidase is the higher-value opportunity associated with OPDIVO QVANTIG. Suppliers need recombinant production, viral-safety controls, potency assays, impurity control, and a reliable cold-chain process. A supplier with an accepted regulatory package can have a material advantage over a lower-cost producer without established biologic documentation.

Device and packaging companies

Subcutaneous delivery creates demand for:

• Prefilled syringes.
• Autoinjectors.
• Dual-chamber or co-packaged systems.
• Low-dead-volume components.
• Compatible elastomers.
• Low-silicone primary containers.
• Automated inspection systems.

The device opportunity is commercially attractive because it can create switching costs independent of the antibody molecule.

What manufacturing and IP barriers affect excipient commercialization?

Excipient supply is subject to manufacturing barriers that can be as important as patent protection.

Critical barriers include:

1. Qualification of alternate suppliers without changing the approved product.
2. Demonstration that impurity profiles do not affect antibody quality.
3. Control of surfactant oxidation and hydrolysis.
4. Consistency of hyaluronidase potency.
5. Aseptic processing and sterile filtration.
6. Extractables and leachables validation.
7. Global change-control filings.
8. Protection of proprietary formulation and process data.

For polysorbate 80, a supplier change can affect oxidation, particle formation, and assay performance. For hyaluronidase, a change can affect local tolerability, activity, and subcutaneous dispersion. These factors make qualified suppliers strategically valuable even when the underlying excipient is off-patent.

What is the revenue exposure to OPDIVO formulation changes?

OPDIVO is one of Bristol Myers Squibb’s largest products. Bristol Myers Squibb reported approximately $9.0 billion in worldwide OPDIVO revenue in 2023 and approximately $9.3 billion in 2024.[6,7] The commercial exposure is therefore substantial even for a seemingly minor formulation change.

The economic impact of excipient strategy arises through:

• Longer shelf life.
• Lower manufacturing loss.
• Reduced particulate rejection.
• Higher filling speeds.
• Lower cold-chain cost.
• Reduced infusion-center labor.
• More convenient subcutaneous administration.
• Improved patient persistence.
• Differentiation from intravenous biosimilars.

OPDIVO QVANTIG may shift value from infusion-center administration toward outpatient and community settings. That shift can increase the value of device compatibility, injection-time reduction, and patient-support infrastructure.

How does OPDIVO compare with competing PD-1 drugs?

Product	Active ingredient	Route strategy	Excipient opportunity
OPDIVO	Nivolumab	Intravenous and subcutaneous with hyaluronidase	High-value surfactant, biologic, and delivery platform
KEYTRUDA	Pembrolizumab	Primarily intravenous; subcutaneous development has been pursued	Competition in high-concentration and route-conversion technologies
LIBTAYO	Cemiplimab	Intravenous	More limited route-specific excipient opportunity
IMFINZI	Durvalumab	Intravenous	Conventional biologic formulation and manufacturing opportunity
TEVIMBRA	Tislelizumab	Intravenous	Regional and global biosimilar competition

The competitive advantage of OPDIVO QVANTIG is not limited to nivolumab. It is also a delivery and administration proposition. A biosimilar that matches the antibody but lacks a comparable subcutaneous presentation may compete first in infusion settings rather than across the full OPDIVO franchise.

What litigation and settlement issues affect OPDIVO?

No Orange Book Paragraph IV litigation framework applies directly because OPDIVO is a biologic. The relevant legal mechanisms are BPCIA patent-exchange procedures, declaratory-judgment actions, patent litigation involving biosimilar applicants, and settlement agreements governing launch dates.

Commercial diligence should monitor:

• FDA Purple Book entries.
• BPCIA notices of commercial marketing.
• Patent-list disclosure and patent-exchange activity.
• Federal district court filings.
• Federal Circuit appeals.
• Patent settlements with biosimilar developers.
• Licensing or co-development agreements for subcutaneous delivery.

A settlement could permit an earlier biosimilar launch while preserving BMS control over a later subcutaneous or combination-product launch. It could also distinguish intravenous nivolumab from nivolumab-hyaluronidase products.

What are the most attractive commercial opportunities?

The strongest opportunities are ranked below.

Opportunity	Attractiveness	Main constraint
Pharmaceutical-grade polysorbate 80	High	Qualification and oxidation control
Recombinant hyaluronidase	Very high	Biologic manufacturing and IP
Subcutaneous delivery devices	High	Combination-product validation
Protein-stability analytics	High	Specialized technical capability
Container-closure systems	Medium to high	Extractables and leachables
Commodity mannitol and saline	Medium	Price competition
Novel surfactants	Medium	Regulatory and comparability burden
Formulation CDMO services	High	Need for biologic scale-up expertise

Key Takeaways

• OPDIVO’s conventional formulation uses mannitol, pentetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection.[1]
• Polysorbate 80 is the most commercially sensitive conventional excipient because oxidation and degradation can affect antibody stability.
• OPDIVO QVANTIG creates a larger opportunity in recombinant hyaluronidase, high-concentration formulation, devices, and subcutaneous delivery.
• The relevant exclusivity framework is the Purple Book and BPCIA, not the Orange Book.
• Baseline 12-year reference-product exclusivity for the original OPDIVO biologic points to December 2026, subject to the statutory definition of first licensure.
• Biosimilar competition will depend on antibody comparability, manufacturing, patent resolution, and whether the entrant can match subcutaneous delivery.
• Commodity excipient sales have lower strategic value than qualified supply of polysorbate 80, hyaluronidase, analytical services, and primary-container systems.
• OPDIVO’s approximately $9 billion annual revenue scale makes formulation reliability and route-of-administration protection commercially material.[6,7]

FAQs About OPDIVO Excipients and Commercial Strategy

Does OPDIVO contain polysorbate 80?

Yes. The FDA label identifies polysorbate 80 as an inactive ingredient in the intravenous OPDIVO formulation.[1]

Is hyaluronidase an excipient in OPDIVO QVANTIG?

Hyaluronidase is a separate active biological component that enables subcutaneous administration. It should not be treated as an ordinary inactive excipient for regulatory, manufacturing, or IP analysis.[2]

Can a biosimilar use the same OPDIVO excipients?

A biosimilar may use the same or different excipients, but it must demonstrate that formulation differences do not affect quality, safety, or efficacy. Surfactant and buffer changes can require extensive comparability work.

Does OPDIVO have an Orange Book patent listing?

No. OPDIVO is a biologic. Its regulatory and patent analysis is conducted through BLA records, the Purple Book, FDA biologics information, patent databases, and litigation records.[4,5]

Which OPDIVO excipient has the highest supply-chain risk?

Recombinant hyaluronidase has the highest strategic supply-chain risk because it requires biologic manufacturing, potency testing, impurity control, and specialized regulatory support. Among conventional excipients, polysorbate 80 has the greatest formulation sensitivity.

References

1. U.S. Food and Drug Administration. (2024). OPDIVO (nivolumab) injection, prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2024). OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) prescribing information. Bristol Myers Squibb.

3. U.S. Food and Drug Administration. (2022). Chemistry, manufacturing, and control changes to an approved application: Certain biological products. Guidance for industry.

4. U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.

5. U.S. Food and Drug Administration. (2024). Approved drug product with therapeutic equivalence evaluations. Orange Book.

6. Bristol Myers Squibb. (2024). 2023 annual report.

7. Bristol Myers Squibb. (2025). 2024 annual report.